Answers are grounded in this paper and cite their sources.
In this issue of Blood, Qin et al demonstrate the ability of chimeric antigen receptor (CAR)-engineered T cells targeted against thymic stromal lymphopoietin receptor (TSLPR) to eradicate disease in several models of B-cell acute lymphoblastic leukemia (B-ALL) that overexpress this protein.
No takes yet. Share an insight, caveat, or question.
Davies et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: